| Autor: |
Moglad E; Department of Pharmaceutics, College of Pharmacy, Prince Sattam bin Abdulaziz University, Alkharj, Saudi Arabia., Elekhnawy E; Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Tanta University, Tanta, Egypt., Alanazi N; Department of Pharmaceutics, College of Pharmacy, Prince Sattam bin Abdulaziz University, Alkharj, Saudi Arabia., Al-Fakhrany OM; Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Tanta University, Tanta, Egypt. |
| Jazyk: |
angličtina |
| Zdroj: |
Biofouling [Biofouling] 2024 Nov; Vol. 40 (10), pp. 801-815. Date of Electronic Publication: 2024 Oct 10. |
| DOI: |
10.1080/08927014.2024.2413652 |
| Abstrakt: |
Simvastatin had minimum inhibitory concentrations of 32 to 128 µg/mL against Klebsiella pneumoniae isolates and hindered the biofilm-formation ability of 58.54% of the isolates. It considerably diminished the bacterial cell counts in the biofilms as revealed by scanning electron microscope. Also, qRT-PCR revealed a downregulation of the biofilm genes (bcsA, wza, and luxS) by simvastatin in 48.78% of the isolates. Moreover, simvastatin has significantly improved the survival of mice and decreased the burden of bacteria in the infected lungs. Also, the histological architecture was substantially improved in the simvastatin-treated group, as the alveolar sacs and bronchioles appeared normal with minimal collagen fiber deposition. The immunohistochemical studies exposed that the TNF-α, NF-kβ, and COX-2 immunostaining considerably declined in the simvastatin-treated group. Furthermore, ELISA exposed that both IL-1β and IL-6 were considerably diminished in the lungs of the simvastatin-treated group. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
